[Comparative analysis of the effectiveness of Botulinum toxin type A - hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm].

Objective: To analyze the effectiveness of Relatox (Botulinum toxin type A - hemagglutinin complex) in comparison with Botox in the treatment of primary idiopathic blepharospasm.

Material and methods: The study included clinical data for 21 patients with blepharospasm who were treated by botulinum therapy with Botox and Relatox for 3 years. The research method is a one-step retrospective analysis of medical data. Injections were carried out with a 3-month interval. On the 6th cycle, the drug was switched to Relatox. The clinical efficacy of the drugs was assessed using an 8-point Jankovich evaluation scale: the average values before the injection and 14 days after it were compared for each procedure.

Results: Mean Jankovich scale scores decreased 2.5-fold for all cycles by the second week after the procedure (4.95 pre-injection vs. 1.8 post-injection), and the mean paired Student's T-criterion for all injections was 7.14 (with a critical value of 2.021 and a significance level of p=0.05). The mean paired Student's T-criterion for Botox was -6.63 and for Relatox -7.5 (with a critical value of 2.021 and a significance level of p=0.05), indicating a high efficacy of both drugs, slightly higher for Relatox.

Conclusion: A consistent trend of increasing efficacy with regular botulinum toxin injections and greater efficacy of Relatox compared to Botox in the treatment of patients with primary idiopathic blepharospasm has been demonstrated.